Immunoglobulin G4-related immune responses to common food antigens in patients with ulcerative colitis and Crohn's disease
Ulcerative colitis (UC) and Crohn's disease (CD) are two major immune-mediated entities of inflammatory bowel diseases (IBD) that could have relapse and remission periods. Both UC and CD occur after environmental triggers in genetically predisposed individuals. However, environmental triggers and immune system interactions are still complex and lesser known. Serum miR-551b-3p is a potential diagnostic biomarker for gastric cancer Gastric cancer (GC) is the second most common cause of cancer-related deaths worldwide, and in Turkey, it is the fourth most common cancer in men and the sixth most common cancer in women. Well-known risk factors of GC are Helicobacter pylori, diets poor in vegetables and fruits, diets high in salt; low socio-economic status, and smoking. miRNAs are approximately 18-24 nt non-coding RNAs. Recent studies have shown that these RNAs can be used to diagnose diseases and to monitor disease progression. miRNAs act on tissue-specific target messenger RNAs (mRNAs) and alter the expression levels of these mRNAs, resulting in cell proliferation, apoptosis, differentiation, cellular response, viral infection, and tumorigenesis. miRNAs can also act on tumor suppression and exhibit oncogenic properties, similar to those exhibited by mRNAs. Given that circulating miRNAs are protected from RNAse-mediated degradation, they are nominated as non-invasive biomarkers in the diagnosis of many diseases. In this issue of the Turkish Journal of Gastroenterology, Bai et al. have studied serum miR-551b-3p as a potential diagnostic biomarker for GC. The researchers collected 103 venous blood samples from 50 patients with GC (GC group) and 53 healthy controls and found that the serum levels of miR-551b-3p were significantly lower in the GC group than in the healthy controls (p=0.000). The serum levels of miR-551b-3p correlated with tumor size (p=0.014), depth of invasion (p=0.001), and tumor-node-metastasis (TNM) stage (p=0.022).
The area under the ROC curve for diagnostic accuracy of serum miR-551b-3p as a GC biomarker was 0.860 (95% CI: 0.787-0.933, p=0.000), with 70% sensitivity and 96.2% specificity. The cut-off point of miR-551b-3p was obtained as 0.0175. In the era of insufficient tumor markers for GC, miR551b-3p could be a potential biomarker for GC, and the results of this trial could be promising. However, these results need to be confirmed with prospective, multi-center studies involving a large sample size. See page 415. 
